SSE

Ping An establishes China's first charitable trust for mangrove ecosystem conservation to promote sustainable development

Retrieved on: 
Friday, October 20, 2023
Carbon, Science, SSE, Environmental protection, Biodiversity, Public Welfare Foundation, Education, ESG, Human, Ping'an, Nature, Trust, Convention center, Gaoligong Mountains, Ecology, Insurance, Forestry, Renewable energy

It is the first charitable trust in China to focus on the conservation of mangrove ecology and aims to protect biodiversity, and promote ecological conservation and sustainable development.

Key Points: 
  • It is the first charitable trust in China to focus on the conservation of mangrove ecology and aims to protect biodiversity, and promote ecological conservation and sustainable development.
  • The Trust was initiated with a donation of RMB10 million from the Shenzhen Ping An Public Welfare Foundation, with Ping An Trust as the trustee.
  • The establishment of the Trust follows Ping An's launch of mangrove carbon sink insurance, furthering the Group's exploration and implementation of ESG principles and sustainable development.
  • Ping An launched China's first "carbon neutrality" charitable trust -  "Ping An Carbon Neutral Green Finance Development Charitable Trust," to support and promote green and low-carbon projects.

Ping An establishes China's first charitable trust for mangrove ecosystem conservation to promote sustainable development

Retrieved on: 
Friday, October 20, 2023
Carbon, Science, SSE, Environmental protection, Biodiversity, Public Welfare Foundation, Education, ESG, Human, Ping'an, Nature, Trust, Convention center, Gaoligong Mountains, Ecology, Insurance, Forestry, Renewable energy

It is the first charitable trust in China to focus on the conservation of mangrove ecology and aims to protect biodiversity, and promote ecological conservation and sustainable development.

Key Points: 
  • It is the first charitable trust in China to focus on the conservation of mangrove ecology and aims to protect biodiversity, and promote ecological conservation and sustainable development.
  • The Trust was initiated with a donation of RMB10 million from the Shenzhen Ping An Public Welfare Foundation, with Ping An Trust as the trustee.
  • The establishment of the Trust follows Ping An's launch of mangrove carbon sink insurance, furthering the Group's exploration and implementation of ESG principles and sustainable development.
  • Ping An launched China's first "carbon neutrality" charitable trust -  "Ping An Carbon Neutral Green Finance Development Charitable Trust," to support and promote green and low-carbon projects.

CNOOC Limited Announces the Train 3 of Tangguh LNG Project Commences Production

Retrieved on: 
Friday, October 20, 2023
Insurance, SSE, HKD, RMB, SEHK, HSSE, PSC, Train (3 Doors Down song), CNOOC Limited, Perception, Natural gas, Limited, LNG, Tangguh gas field

HONG KONG, Oct. 19, 2023 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that the first LNG cargo from the newly-built liquefaction train (Train 3) of the Tangguh LNG project in Indonesia has been delivered, marking the safe commencement of the Train 3 of Tangguh LNG project.

Key Points: 
  • HONG KONG, Oct. 19, 2023 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that the first LNG cargo from the newly-built liquefaction train (Train 3) of the Tangguh LNG project in Indonesia has been delivered, marking the safe commencement of the Train 3 of Tangguh LNG project.
  • Tangguh LNG project is located in Papua Barat Province in Indonesia, consisting of 6 offshore gas fields under 3 PSCs.
  • Train 3 brings the total plant capacity to 11.4 mtpa, which further consolidates the position of Tangguh LNG project as the largest gas field and the largest LNG production hub in Indonesia.
  • CNOOC Muturi Limited, a wholly-owned subsidiary of the Company, holds a 13.90% interest in Tangguh project.

Empowering the Future: IDTechEx Discusses the Progress of Solid-State Battery Technology

Retrieved on: 
Wednesday, October 18, 2023
Hydrogen, Science, Toyota, CTP, SSE, Attention, OPEX, KPI-driven code analysis, Temperature, Lithium polymer battery, Life, JS Taigei (SS-513), CAPEX, Safety, Players, Research, Risk, SSB, SSBS S1, Daimler, Mercedes-Benz, EVS, Electrolyte, Longevity, Lithium, Electric battery, Extractive metallurgy

As the demand for higher performance and safer energy storage solutions grows, SSBs have emerged as a frontrunner in the race for next-generation battery technology.

Key Points: 
  • As the demand for higher performance and safer energy storage solutions grows, SSBs have emerged as a frontrunner in the race for next-generation battery technology.
  • These components, combined in various configurations, create the Li-ion battery modules and packs that power our devices and vehicles.
  • SSEs also open the door to using different cathode and anode materials, expanding the possibilities of battery design.
  • Enhanced Safety: SSBs are considered the "holy grail" of battery technology due to their improved safety profile.

Empowering the Future: IDTechEx Discusses the Progress of Solid-State Battery Technology

Retrieved on: 
Wednesday, October 18, 2023
Hydrogen, Science, Toyota, CTP, SSE, Attention, OPEX, KPI-driven code analysis, Temperature, Lithium polymer battery, Life, JS Taigei (SS-513), CAPEX, Safety, Players, Research, Risk, SSB, SSBS S1, Daimler, Mercedes-Benz, EVS, Electrolyte, Longevity, Lithium, Electric battery, Extractive metallurgy

As the demand for higher performance and safer energy storage solutions grows, SSBs have emerged as a frontrunner in the race for next-generation battery technology.

Key Points: 
  • As the demand for higher performance and safer energy storage solutions grows, SSBs have emerged as a frontrunner in the race for next-generation battery technology.
  • These components, combined in various configurations, create the Li-ion battery modules and packs that power our devices and vehicles.
  • SSEs also open the door to using different cathode and anode materials, expanding the possibilities of battery design.
  • Enhanced Safety: SSBs are considered the "holy grail" of battery technology due to their improved safety profile.

BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SSE, Congress, Abstract, ORR, Tislelizumab, Cisplatin, OS, PD-L1, XELOX, BGNE, Survival, CEST, ESMO, ITT, Oxaliplatin, Kuwait Cancer Control Center, PFS, European Society for Medical Oncology, European Society of Gynaecological Oncology, FP, Patient, Sun, Pharmaceutical industry, BeiGene

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
  • Study results will be featured as a late-breaking oral presentation on October 21 at 5:25 p.m. CEST at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract #LBA80).
  • “These data show that tislelizumab plus chemotherapy resulted in significant overall survival improvement compared with chemotherapy alone in the intent-to-treat patient group.
  • Median progression-free survival (PFS) for tislelizumab plus chemotherapy was 6.9 months vs. 6.2 months respectively; (HR: 0.78 [95% CI: 0.67, 0.90]).

Salem Sports Events, LLC Announces Appointment of Chief Revenue Officer

Retrieved on: 
Tuesday, October 17, 2023
Sports, General Sports, Construction & Property, Interior Design, Marketing, Communications, Fashion, Bridal, Retail, Other Construction & Property, Restaurant, Bar, SSE, Sirius XM PGA Tour Radio, Senior, Event segment, American Rental Association, ARA, Auerbach, PGA Tour, Nike, Management

Salem Sports Events (SSE), LLC, the leading provider of innovative and custom designed interiors for companies like the PGA Tour, Nike, and Titos, announces the addition of James Auerbach as Chief Revenue Officer (CRO) and part of its executive leadership team.

Key Points: 
  • Salem Sports Events (SSE), LLC, the leading provider of innovative and custom designed interiors for companies like the PGA Tour, Nike, and Titos, announces the addition of James Auerbach as Chief Revenue Officer (CRO) and part of its executive leadership team.
  • “We are excited to welcome James to our executive team at SSE,” said Jeff Ickes, CEO at Salem Sports Events.
  • His proven track record leading cross-functional teams, with a concentration on profitable revenue growth, exceeding customer expectations, and employee development is a perfect fit for Salem Sports Events.
  • “I am honored to be joining such a respected company in the live events industry like Salem Sport Events," Auerbach said.

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, SSE, Congress, NSCLC, Abstract, Tislelizumab, BeiGene, BGNE, CEST, ESMO, EFS, Rollcage Stage II, Neoadjuvant therapy, European Society for Medical Oncology, PCR, European Society of Gynaecological Oncology, Patient, MPR, Medical imaging, Dentistry, Pharmaceutical industry

The tislelizumab plus chemotherapy regimen also showed a statistically significant improvement in pathological complete response (pCR), the key secondary endpoint, after neoadjuvant therapy versus chemotherapy.

Key Points: 
  • The tislelizumab plus chemotherapy regimen also showed a statistically significant improvement in pathological complete response (pCR), the key secondary endpoint, after neoadjuvant therapy versus chemotherapy.
  • In the study, 56.2% of NSCLC patients treated with tislelizumab in combination with chemotherapy before surgery achieved MPR, compared to 15.0% of patients treated with chemotherapy alone (difference: 41.1%; 95% CI: 33.2-49.1, p
  • "Lung cancer remains the most common type of cancer and the leading cause of cancer-related death worldwide.
  • These results add to the growing evidence suggesting the potential benefits of tislelizumab in treating patients with NSCLC.”

Fortinet Expands Its Global SASE Points-of-Presence with Google Cloud

Retrieved on: 
Monday, October 16, 2023
Cloud, SSE, Partnership, Certification, Education outreach, Network, Universal, Organization, Software as a service, GM, Google Cloud, Fortinet, SD, NSE, TAA, Architecture, Secure access service edge, SASE, POP, SWG, ROI, CASB, Firewall, Persistent organic pollutant, ZTNA, Global Outbreak Alert and Response Network, Research, Network equipment provider, Online shopping

Fortinet ® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced the expansion of its SASE Points-of-Presence (POPs) to new locations through a partnership with Google Cloud.

Key Points: 
  • Fortinet ® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced the expansion of its SASE Points-of-Presence (POPs) to new locations through a partnership with Google Cloud.
  • The partnership allows Fortinet to leverage Google Cloud’s global network edge locations closest to their regions of presence, which deliver dedicated interconnect and 99.99% service availability, to accelerate the expansion of Fortinet’s Universal SASE solution .
  • “By leveraging Google Cloud, Fortinet Universal SASE is even better positioned to serve a more extensive global footprint, ensuring that customers can seamlessly connect and secure their hybrid workforces to critical applications,” said Michael Xie, Founder, President, and Chief Technology Officer of Fortinet.
  • “This partnership will expand our global POP resources and accelerate customer adoption of Fortinet’s Universal SASE solution.

BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SSE, Congress, European, Food, Abstract, TIS, PD-L1, Trial of the century, Programmed cell death protein 1, BGNE, Medicine, OCI, FDA, ESMO, Biologics license application, MSI-H, Neoplasm, Regulation of tobacco by the U.S. Food and Drug Administration, European Society for Medical Oncology, Affirmative action, ESCC, Pharmaceutical industry, Tislelizumab, BeiGene, Patient, EU

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023.
  • “Tislelizumab is the cornerstone of BeiGene’s diverse pipeline of pan-solid tumor programs for the next wave of immuno-oncology targets.
  • Additionally, the U.S. Food and Drug Administration (FDA) recently accepted for review a Biologics License Application for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC.
  • Long-term Follow-up of a Phase 2 Study of Tislelizumab (TIS) Monotherapy in Patients (pts) With Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR) Solid Tumors.